A listing of Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Low-dose computed tomography (LDCT) screening reduces mortality among current and former smokers at high risk for lung cancer, and is widely recommended by national guidelines. LDCT also increases access to care and thus provides an opportunity to deliver smoking cessation interventions to current smokers in conjunction with this screening. As …
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer.
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-0482, MK-5890, MK-4830) in combination with pembrolizumab based therapy in patients with PD-(L)1 refractory NSCLC in a rolling-arm design
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation). Patients with driver mutations in EGFR, ALK, …
This study is being done to answer the following questions: Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer? Does additional treatment …
This trial is testing MK-7684A when given in combination with chemotherapy plus radiation therapy (concurrent chemoradiotherapy or cCRT). This trial is for people with stage 3 non-small cell lung cancer (NSCLC). Receiving cCRT is part of the standard treatment for patients with stage 3 NSCLC. MK-7684A, an experimental treatment, is …
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed …
This is a screening study to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
the purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC). Eligible subjects will be those with NSCLC.